Purpose Obesity may alter mononuclear phagocyte system (MPS) function and the pharmacology and efficacy of nanoparticles therapies, such as PEGylated liposomal doxorubicin (PLD). We aimed to evaluate the relationships between hormone and chemokine mediators of MPS function and the pharmacokinetic (PK) exposure of PLD in obese and normal weight patients with ovarian and endometrial cancer. Methods Hormone and chemokine mediators in obese and normal weight ovarian and endometrial cancer patients were measured. A separate pharmacology study was performed that evaluated the relationship between serum hormone concentrations, MPS function, and PK disposition of PLD in refractory ovarian cancer patients. Results Univariate analysis revealed a significant relationship between serum estradiol and body mass index (OR 8.64, 95% CI 2.67-28.0, p < 0.001). Estrone and testosterone concentrations were positively correlated with MPS function (ρ = 0.57 and 0.53, p = 0.14 and 0.18, respectively) and inversely correlated with PLD PK exposure (ρ = − 0.75 and − 0.76, respectively, p = 0.02 for both). Conclusions Higher MPS function resulting in reduced PLD exposure is a potential mechanism for reduced efficacy of PLD and other nanoparticles observed in obese patients with cancer. PK simulations suggest higher doses of PLD are required in obese patients to achieve similar exposures as standard dosing in normal weight patients.
Introduction
Nanotechnology offers a number of advantages over traditional drug delivery systems for the treatment of solid tumors [1, 2] . Advantages of nanoparticles (NP) in solid tumor treatment include increased blood circulation time, enhanced delivery of entrapped drug to tumors, improved therapeutic time and a reduction in off target effects [1, 2] . The abnormal blood and lymphatic vasculature allow for selective delivery and accumulation of NPs at tumor sites via the enhanced permeability and retention effect (EPR) [3] . Unfortunately, only a limited number of NPs have become clinically successful due to high inter-patient and intra-patient variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of NPs [4, 5] .
Liposomes, lipid vesicles formed by a lipid bilayer surrounding an aqueous core, are the most common NP drug carriers approved by the FDA [6] . One such carrier approved for use in humans is PEGylated liposomal doxorubicin (PLD, Doxil ® ). In a meta-analysis of inter-patient variability in the PK of liposomal anticancer agents compared to small molecule formulations of the agent, the PK variability of liposomal drugs, measured as coefficient of variance (CV%) of area under the concentration versus time curve (AUC), was significantly greater [5] . This PK variability is significant as it has been associated with high variability in the efficacy and toxicity of NPs [5, 7, 8] .
Bone marrow-derived progenitors, blood monocytes, and tissue macrophages comprise the mononuclear phagocyte system (MPS) [9] . The MPS recognizes, internalizes and eventually clears NPs. The immunological properties of NPs trigger the MPS [10] . Identifying factors to predict the PK and PD of NPs to allow for individualized dosing may further enhance tolerability while preserving or improving efficacy [11] . Associations between the PK variability of NPs and patient age, gender, type of cancer and the function of monocytes in patients with cancer have been previously reported [12] [13] [14] . In addition, the effects of body habitus, which is defined as the physical and constitutional characteristics of underweight, normal weight and overweight patients, on NP PK and PD have been evaluated [8, [13] [14] [15] [16] . In these studies, patients with a higher ratio of total to ideal body weight had increased clearance of PEGylated liposomal agents [15, 16] . In addition, the PK variability of NPs and other carrier-mediated agents (CMAs) is even greater in obese patients. The factors affecting the PK of NPs and CMAs in obese patients are unclear, but may be attributed to the effects of serum hormones on MPS function and ultimately CMA clearance [17] . This is supported by a series of studies demonstrating that serum hormones, such as estrogens and testosterone, modulate immune system activity and macrophage phagocytic and chemotactic function. Of particular interest are the reports of various estrogens stimulating the phagocytic activity of the MPS in vitro [18] [19] [20] .
Obesity has reached epidemic proportions in the United States. Based on body mass index (BMI), over 30% of adults are obese and 65% are overweight [21] [22] [23] [24] . Obesity has been linked to an increased risk of many cancers, including breast, colon, endometrial, ovarian and others [11] . Currently, there are approximately 1.5 million new cancer cases and half a million cancer-related deaths per year, with nearly one in five associated with obesity [11, [25] [26] [27] [28] . Obesity has been associated with increased risk and worse outcomes for both endometrial and ovarian cancer, which are both treated with PLD [11, 29] . We hypothesize that obesity and obesityrelated factors alter the PK and PD of NPs, such as PLD. Specifically, obese patients will have a higher distribution of NPs to adipose tissue and higher circulating levels of serum hormones and chemokines which lead to higher MPS function, higher NP clearance, and ultimately reduced NP tumor exposure. These hormone and chemokine mediators of MPS function and NP PK and PD have not been extensively evaluated in patients with cancer and especially not as related to body habitus. To test this hypothesis, we measured hormone and chemokine mediators in existing blood samples from obese and normal weight patients with ovarian and endometrial cancer enrolled on the UNC Health Registry/Cancer Survivorship Cohort (UNC CSC). The UNC CSC is a registry of cancer survivors with available interview data and clinically annotated biospecimens who consent to the use of their data and specimens for future research. Specific aims of this study included profiling hormone and chemokine mediators of MPS function and NP PK in obese (BMI > 30 kg/ 1 3 m 2 ) and normal weight (BMI = 18.5-24.9 kg/m 2 ) patients with ovarian and endometrial cancer. In addition, a separate pharmacology study was performed that evaluated the relationship between serum hormone concentrations, MPS function, and the PK exposure of PLD in patients with refractory ovarian cancer.
Materials and methods

Exposure of hormones and chemokines
Patients with ovarian and endometrial cancer were selected based on the high incidence of obesity in these patients and the potential lower response to NP therapy in obese compared with normal weight patients [11, [29] [30] [31] [32] [33] [34] . Postmenopausal Caucasian women were selected to maximize the ability to detect differences in hormone and chemokine exposures associated with obesity. Patients were classified as being either obese or normal weight based on BMI. According to the World Health Organization (WHO), BMI, a simple weight-to-height relationship, is used to classify body habitus in the adult population [35, 36] Patient samples were obtained from the UNC CSC repository. The Biospecimen Processing Core Facility (BSP) functioned as the processing, biobanking, and repository management core for the UNC CSC. The concentration of estradiol, estrone, DHT and total testosterone was measured in serum (500 μL) and the concentration of CCL2 and CCL5 chemokines was measured in plasma (500 μL) from each patient at the UNC Cytokine and Biomarker Core Facility [27, 28] . Hormones were measured using an existing ELISA assays [12, 37] . A multiplex cytokine/chemokine assay (Millipore, Billerica, MA, USA) was performed for quantification of CCL2 and CCL5 according to manufacturer's protocol.
Pharmacology studies of PLD in patients with ovarian cancer
This study was approved by the University of North Carolina IRB prior to enrolling any participants. Ten women ≥ 18 years of age receiving PLD, alone or in combination with carboplatin as the standard treatment for refractory ovarian cancer were enrolled on the study. All patients had previously undergone bilateral salpingo-oophorectomy prior to enrollment. Six patients received PLD monotherapy at a dose of 40 mg/m 2 and four patients received PLD at a dose of 30 mg/m 2 with concurrent carboplatin (AUC = 5 mg/mL/ min).
The concentration of estradiol, estrone, DHT and total testosterone was measured in serum (500 μL) and concentration of CCL2 and CCL5 chemokines was measured in plasma (500 μL) prior to administration of PLD on cycle 1 [27, 28] . The number and function of MPS cells (monocytes and dendritic cells) in blood were measured via flow cytometry in the University of North Carolina Flow Cytometry Core Facility using a Dako CyAn flow cytometer, and data were analyzed using FlowJo software (v7.6.5). For the oxidative burst assay, monocytes were gated based on light scatter properties (forward scatter versus side scatter) and subsequently plotted for histogram analysis. The proportion of positive cells was determined as those events which shifted to the right out of the "negative" region. Mean fluorescent intensity (MFI) of the positive cell population served as an index of oxidative burst. Oxidative burst of monocytes was assessed in response to opsonized non-fluorescent E. coli as a stimulus. Following a 10-min exposure to the stimulus, non-fluorescent dihydrorhodamine 123 (Orpegen Pharma, San Diego, CA, USA) was added to samples as a fluorogenic substrate, which, following intracellular oxidation, was converted to fluorescent rhodamine 123. MFI of rhodamine 123 fluorescence served as a quantitative measure of intracellular oxidative activity. Hormone and chemokine concentrations were compared to MPS function and PLD PK parameters (i.e., clearance and plasma AUC).
Blood samples (5 mL) for PK studies were obtained prior to PLD administration, at the end of infusion, and at hours 2, 6, 24, 48, 72, 96, 168, and on day 28 (prior to second cycle of PLD) after administration of PLD. Samples were immediately placed on ice after collection, and centrifuged to plasma within 5 min at 4 °C. Plasma was stored at 4 °C until processed to encapsulated and released doxorubicin using solid phase separation and HPLC with fluorescence detection [12] . PK parameters were calculated using noncompartmental analysis (Phoenix WinNonlin, v6.03).
Statistical analyses
In the study in normal weight and obese patients with ovarian or endometrial cancer, correlations between serum hormone and chemokine concentration and BMI were analyzed using univariate and multivariate logistic regression models generated by SAS software (v9.4; SAS Institute Inc., Cary, NC, USA). The concentrations of hormones and chemokines were dichotomized at the median to convert them from a continuous to a discrete variable to use an odds ratio. Concentrations below the median were considered "low concentration" and concentrations above the median were considered "high concentration".
In the pharmacology study in patients with ovarian cancer, relationships between hormones, chemokines, MPS function and PLD PK were analyzed via exponential regression and spearman correlation using SAS.
Results
Exposure of hormones and chemokines
A summary of patient demographics for this study is included in Table 1 . The results of the univariate analysis for CCL2, CCL5, estrone, estradiol, total testosterone and dihydrotestosterone (DHT) are listed in Tables 2 and 3 . The odds ratio was significant for the relationship between estradiol and BMI (P = 0.0003). The odds of a high concentration of estradiol among obese patients were 8.64 times that among normal weight patients (95% CI 2.67-28.0). A multivariate analysis was then performed in all patients to assess the effect of other factors, including BMI, age at diagnosis, stage and other hormones and chemokines on estradiol concentration. This multivariate analysis revealed a significant relationship between BMI and estradiol concentration (P = 0.0023).
The univariate analysis was repeated with obese and normal weight patients stratified by cancer type. In patients with ovarian cancer (13 obese, 9 normal weight), odds ratios were non-significant. In patients with endometrial cancer (20 obese, 19 normal weight), odds ratio for the relationship between serum estradiol and BMI increased, indicating a stronger relationship than that between estradiol and BMI in all patients (e.g. in patients with ovarian or endometrial) (OR 11.20, 95% CI 2.51-50.08, P = 0.0016). These results can be found in Tables 2, 3 and 4. 
Pharmacology studies of PLD in patients with ovarian cancer
Ten patients with refractory ovarian cancer who received PLD as treatment participated in this pharmacology study. Estrogen and DHT concentrations were below the lower limit of quantification (10 pg/ml for estrogen and 50 pg/ml for DHT) for the majority of the patients and thus were not included in the analyses. A summary of the patient demographics, chemokine and hormone levels, and PLD PK for this study are included in Table 5 .
We also evaluated the relationship between serum hormone concentrations and MPS function. MPS function in monocytes and DCs in blood was measured as the generation of reactive oxygen species (ROS) [7] . Blood samples for MPS function studies were obtained prior to PLD administration. There was a positive relationship between estrone and testosterone concentrations and the generation of ROS in monocytes and DCs in blood (ρ = 0.57 and 0.53, respectively) (Fig. 1) .
There also was an inverse relationship between estrone and testosterone and encapsulated doxorubicin AUC 0−∞ in plasma (ρ = − 0.75 and − 0.76, respectively) (Fig. 2) . There was a positive relationship between estrone and testosterone and encapsulated doxorubicin clearance in plasma (ρ = 0.60 and 0.60, respectively; data not shown). When patients were subdivided based on PLD monotherapy (n = 6), there was a stronger correlation between estrone and testosterone concentrations with encapsulated doxorubicin AUC (R 2 = 0.57 and 0.59, respectively) and clearance (R 2 = 0.86 and 0.88, respectively) (data not shown). No significant relationship was found between patient TBW, BMI, and hormone concentrations. In addition, there was no correlation between baseline exposures of chemokines and MPS function or PLD PK (data not shown).
The BSA (1.31-fold), BMI (1.86-fold) and estradiol concentrations (2.01-fold) were significantly higher in obese patients compared with normal weight patients with endometrial cancer (Table 1 ). In addition, the BSA (1.15-fold), BMI (1.38-fold) and estradiol concentrations (1.35-fold) were significantly higher in obese patients compared with normal weight patients with ovarian cancer (Table 1) . As these factors are associated with reduced plasma exposure of PLD, PK simulations were performed to determine what dose of PLD would be required to obtain similar plasma AUC of encapsulated doxorubicin in obese patients compared with normal weight patients. The mean plasma AUC of encapsulated doxorubicin after administration of PLD at 40 mg/m 2 (standard clinical dose of single agent PLD) in normal weight patients was 2820 μg/mL h. In obese patients with endometrial cancer, the doses of PLD required to achieve similar plasma exposures of PLD based on differences in BSA, BMI and estradiol were 52, 74 and 81 mg/ m 2 , respectively. In obese patients with ovarian cancer, the doses of PLD required to achieve similar plasma exposures of PLD based on differences in BSA, BMI and estradiol were 46, 55 and 54 mg/m 2 , respectively. As there are significant differences in estrogen-like hormones between obese and normal weight patients and these hormones have been reported to significantly affect MPS function and the PK of PLD, the higher dose of PLD based on these hormonal factors in obese patients may be the most clinically relevant.
Discussion
Obese patients are at an increased risk of developing cancer, having a recurrence of their cancer, and dying from their disease [38] . Furthermore, inter-patient variability in the PK and PD of NPs is greater in obese patients. Moreover, the efficacy of NPs of anticancer agents appears to be reduced in obese patients [13, 16, 21, 39] . Our group has demonstrated in mouse-models that NPs preferentially distribute to adipose tissue versus muscle in a study that evaluated the exposures of small molecule CKD-602, a camptothecin analogue, and a PEGylated liposomal formulation of CKD-602 (S-CKD-602). There was a 3.8-fold higher ratio of CKD-602 sum total exposure in fat to muscle after administration of S-CKD-602 as compared with CKD-602 [40] . The increased distribution of NPs to adipose results in an increased volume of distribution, reduced accumulation in tumors, and ultimately decreased efficacy. However, when comparing PK differences in obese and normal weight patients, nearly tenfold differences were observed in plasma indicating a second, more dominant, mechanism associated with lower plasma exposure of NPs [13] . The second mechanism thought to be responsible for reduced plasma exposure of NPs in obese patients is related to higher blood clearance of NPs. Previous studies have demonstrated the impact MPS function and its mediators on NP PK and PD [14, 40] . The current studies sought to test the hypothesis that obese ) 1.83 ± 0.17 PLD cycles received (#) 3.2 ± 1.9 Baseline serum hormone concentrations Estrone (pg/mL) 22.7 ± 11.1 Testosterone, total (ng/dL) 11.7 ± 5.0 Estrogen (pg/mL) BQL Dihydrotestosterone (pg/mL) BQL Baseline serum chemokine concentrations CCL2 (pg/mL) 242.3 ± 70.8 CCL5 (pg/mL) 2175 ± 2764.1 Encapsulated Doxorubicin PK parameters Clearance (ml/h) 25.9 ± 12.0 AUC 0−infinity (h × ng/mL) 2,867,933 ± 973,734 AUC 0−infinity % extrapolated (%)
14.6 ± 18.5 Volume of distribution (L) 2.5 ± 0.6 Elimination rate constant (1/h) 0.011 ± 0.008
76.3 ± 25.5 There was a the direct relationship between serum hormone concentrations of estrone (a) and total testosterone (b), and oxidative burst activity in monocytes stimulated with E. coli at baseline in patients with ovarian cancer treated with PLD alone or in combination with carboplatin patients with cancer have higher levels of hormones and chemokines and that these elevated factors alter MPS function and the PK and PD of NPs, such as PLD. These studies were performed in patients with ovarian and endometrial cancer who have a high incidence of obesity and in whom PLD is used as a treatment.
The results of the CSC study demonstrated a strong positive association between estradiol and BMI (OR 8.64, 95% CI 2.67-28.0, P = 0.0003) in all patients. Moreover, this relationship was only significant between estradiol and BMI in patients with endometrial cancer (Table 4 ; OR 11.20, 95% CI 2.51-50.08, P = 0.002). This supports our hypothesis that obese patients have higher circulating levels of hormones. While the odds ratios for the relationship between estrone and BMI (Tables 2, 3 ; OR 1.85, 95% CI 0.66-5.21, P = 0.242) and testosterone and BMI (Tables 2,  3 ; OR 2.14, 95% CI 0.76-6.06, P = 0.152) trended in the direction expected according to our hypothesis, we would have expected statically significant relationships between all hormones and BMI. Given that estrone and estradiol are readily interconverted by 17β-hydroxysteroid dehydrogenase (17β-HSD) and that testosterone can be converted by Cytochrome P450 Family 19 (CYP19) into estradiol, a significant relationship between the concentration of estrone and BMI and the concentration of testosterone and BMI may be absent because enzyme kinetics in adipose tissue may favor conversion of these hormones to estradiol. A similar explanation is possible for the absence of a significant relationship between DHT and BMI. In adipocytes, testosterone can be converted by CYP19 into estradiol or by SR5A1 into DHT [41] . If testosterone is being shunted to the estradiol pathway, there may not be sufficient reserves for the generation of DHT, thus preventing the detection of a relationship between DHT and BMI.
The odds ratio for the relationship between estradiol and BMI was significant for patients with endometrial cancer, but not in patients with ovarian cancer, though this may be due to small sample size. This may also be due to a significant difference in the BMI of obese patients with endometrial cancer compared with ovarian cancer. The mean ± SD BMI for the obese patients with endometrial cancer and ovarian cancer were 46.26 ± 4.41 and 32.78 ± 3.48, respectively. All obese patients with endometrial cancer enrolled in the study were considered morbidly obese with BMIs > 40, ranging from 42.2 to 61.2. The BMIs for obese patients with ovarian cancer ranged from 30.2 to 40.7 with only one of the patients having a BMI > 40. The differences in the magnitude of obesity offer a possible explanation for the lack of continuity in the results between patients with endometrial and ovarian cancer. It may be that the relationship between hormone concentration and BMI does not become significant until patients are morbidly obese. Additional studies are needed to evaluate these factors.
Based on the findings of the first observational study, we performed a pharmacology study in patients with refractory ovarian cancer to evaluate the relationship between serum hormone levels, MPS function in blood and PLD PK disposition. Our findings indicate that patients with higher serum estrone had higher MPS function (as measured by generation of ROS; Fig. 1a ) and lower plasma exposure of encapsulated doxorubicin (Fig. 2a) . Patient body weight and BMI were not found to be associated with estrone concentrations in patients with ovarian cancer, suggesting phenotypic and/or genotypic variations in estrone production in adipose tissue in these patients or that the influence of BMI only occurs in patients that are morbidly obese, which are consistent with the other results of this study. The exact reasons for differences in these hormone levels between the observational and pharmacology studies are unknown. However, the difference in detectable hormone concentrations between the study populations may be indicative of differences in disease burden. Patients included in the pharmacology study had all previously undergone bilateral salpingo oopherectryomy, were recently relapsed, and were receiving active treatment at the time of study, whereas patients included in the observational study had not received treatment in the 6 months prior to the samples being collected.
In all of the PK endpoints analyzed in the study, the relationship between serum hormone concentrations and PLD PK disposition appeared to be strongest in the six patients who received PLD monotherapy. This finding may be explained by a possible influence of concurrent carboplatin therapy on monocyte function and chemotaxis and subsequent alteration in the PK of PLD and other NPs, which would not have been measured by MPS function prior to drug administration [7, 42] .
Patients with ovarian cancer have a greater response to PLD than patients with endometrial cancer, as such PLD is approved for the treatment of ovarian cancer but not endometrial cancer [43, 44] . We hypothesized that the decreased efficacy of PLD in patients with endometrial cancer, especially as compared to the efficacy of small molecule doxorubicin in endometrial cancer and efficacy of PLD in patients with ovarian cancer, may be due to an increased incidence of morbid obesity and higher serum estradiol, which leads to higher MPS function and PLD clearance and ultimately lower exposures of PLD in blood and tumors. The observational study reported significantly higher BMIs and a greater association between BMI and estradiol exposures in patients with endometrial cancer compared with ovarian cancer. In addition, the pharmacology study demonstrated a relationship between serum testosterone and estrone concentrations with MPS function and PLD PK among ovarian cancer cases. These studies suggest that serum hormone concentrations and MPS function are potentially useful for individualizing the dose of PLD and other NPs in obese patients with cancer. Moreover, these results suggest that obese patients with ovarian cancer, and especially endometrial cancer, require a higher dose of PLD to achieve similar plasma exposures to patients that are normal weight. These results are somewhat surprising given that it is standard for PLD to be dosed based on BSA (e.g., 40 mg/m 2 ). Moreover, these results indicate that additional physiological factors associated with morbid obesity in the endometrial cancer patients may contribute to these findings. Our PK simulations based on differences in serum estradiol concentrations in obese and normal weight patients suggest a PLD dose of 54-81 mg/m 2 is required in obese patients to achieve a similar plasma exposure as a PLD dose of 40 mg/m 2 in normal weight patients. However, a limitation of the current study is that the small sample size did not allow enough power to stratify patients into categories of obese and morbidly obese. Thus, larger prospective studies are needed to confirm these results and to further understand the relationship between obesity, hormones, MPS function and the PK and PD of nanoparticles, such as PLD, in obese patients with different types of cancer. The American Society of Clinical Oncology (ASCO) reports that 40% of obese patients receive insufficient chemotherapy doses and exposures, which may lead to reduced efficacy, and recommends that PK studies are needed to guide appropriate dosing of anticancer agents in overweight and obese patients [45] . Our results suggest the magnitude of under dosing of liposomal, carrier-mediated and biological anticancer agents in obese patients may be significantly greater than that for standard small molecule anticancer agents.
